FDA Reports Oseltamivir Shortage Amid Discontinuation

FDA Reports Oseltamivir Phosphate Capsule Shortage Ahead of Discontinuation

On January 14, 2025, the FDA added oseltamivir phosphate capsules (generic Tamiflu) to its Drug Shortages Database with a "Currently in Shortage" designation. The agency reports that Amneal Pharmaceuticals LLC, the sole supplier of generic oseltamivir 30 mg, 45 mg, and 75 mg capsules, has discontinued manufacturing and plans to deplete existing inventory by February 2025. This creates immediate sourcing pressure for wholesale drug distributors and specialty pharmacies during mid-flu season.

Regulatory Context

The FDA Drug Shortages Database is maintained under Section 506C of the Federal Food, Drug, and Cosmetic Act, which requires manufacturers to notify FDA at least six months before discontinuing a drug in the CDRH List of Medically Necessary Drugs. Oseltamivir phosphate capsules meet FDA's definition of medically necessary: they are used to treat or prevent serious disease with no adequate alternative. The statute mandates FDA report active shortages and estimated resolution dates when available.

Oseltamivir is an antiviral medication indicated for treatment and prophylaxis of influenza A and B in patients 1 year and older. The drug is classified under NDA 021087 (brand name Tamiflu, marketed by Genentech) with multiple approved generic versions. Amneal's 30 mg, 45 mg, and 75 mg capsule presentations received FDA approval under ANDA 065525, ANDA 065526, and ANDA 065527 respectively.

FDA does not regulate drug pricing or mandate manufacturers continue production. When a sole-source generic manufacturer discontinues a product, the agency works with remaining suppliers to increase output, but cannot compel new market entry.

Key Details

FDA's January 14, 2025 shortage entry specifies:

• Affected presentations: Oseltamivir phosphate 30 mg capsules, 45 mg capsules, and 75 mg capsules (Amneal Pharmaceuticals LLC)
• Reason for shortage: Discontinuation of production
• Estimated resupply date: None provided (product being discontinued)
• Alternative presentations available: Oseltamivir phosphate powder for oral suspension (12 mg/mL and 6 mg/mL) remains available from multiple manufacturers. Capsules in other strengths (not manufactured by Amneal) are not listed as short.

Amneal notified FDA of the discontinuation in advance under 506C requirements, but the timing—announced mid-flu season with inventory depletion by February—compresses the market adjustment window. Flu season in the U.S. typically peaks between December and February, making this a high-demand period for oseltamivir.

The shortage entry does not indicate broader oseltamivir market disruption beyond Amneal's capsule presentations. Brand Tamiflu capsules (Genentech) and other approved generics remain on the market, but wholesale acquisition costs for these alternatives may differ from Amneal's pricing.

Impact on Wholesale Drug Distributors

Wholesale drug distributors face three immediate operational challenges:

Inventory reallocation: Distributors holding Amneal oseltamivir capsule inventory must communicate depletion timelines to downstream customers. Standing orders for Amneal presentations will require substitution with alternative manufacturers or presentations. Distributors with automated replenishment systems must update NDC-level availability to prevent unfillable orders.

Sourcing and contracting: Specialty pharmacies and health systems with formulary preferences for specific capsule strengths must source alternatives. Distributors may need to expedite contracting with alternative generic suppliers or increase allocations of brand Tamiflu. Price reconciliation may be required if contracted rates were specific to Amneal's products.

Regulatory documentation: For entities operating under DSCSA transaction history and transaction information requirements (21 CFR Part 581), the discontinuation does not change serialization or lot-level tracking obligations for remaining Amneal inventory. However, distributors must ensure ATP (authorized trading partner) verification extends to any newly sourced alternative manufacturers.

The powder for oral suspension alternative requires different handling and dispensing workflows than capsules, particularly for retail and specialty pharmacies without compounding capabilities. Distributors serving pediatric specialty markets may see increased demand for suspension formulations, as the 30 mg and 45 mg capsule strengths are commonly prescribed for weight-based pediatric dosing.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA registration—a prerequisite for legally distributing prescription drugs like oseltamivir in interstate commerce. The directory's average compliance score of 51/100 places the industry in the "Fair" tier, indicating that while most entities maintain basic licensure and registration, fewer have achieved NABP accreditation (only 63 entities) or maintain perfect regulatory records.

The oseltamivir shortage creates a stress test for distributors in the lower compliance tiers. Entities scored "Poor" (38 distributors) or "Minimal" (9 distributors) may lack the vendor diversity, inventory management systems, or ATP verification processes needed to rapidly pivot sourcing when a sole-source generic discontinues. Conversely, the 28 "Excellent"-scored entities typically maintain multi-source strategies and formal shortage response protocols.

Distributors with recalls on record (73 entities in the directory) should exercise particular caution when sourcing alternative oseltamivir suppliers. A product shortage increases pressure to accept allocations from unfamiliar manufacturers, but prior recall history suggests operational gaps in vendor qualification or lot-level verification that could compound risk during rapid sourcing.

Practical Guidance for QA and Compliance Teams

• Verify alternative supplier compliance: Use ColdChainCheck's directory to cross-reference FDA registration status and NABP accreditation for any new oseltamivir suppliers. Entities without active FDA registration (41 of 1,275 in the directory hold expired or suspended registrations) cannot legally distribute prescription drugs under 21 USC 360.

• Document sourcing decisions: If substituting Amneal presentations with alternative manufacturers, maintain ATP verification records and updated transaction documentation. The DSCSA's November 2024 enforcement deadline makes lot-level provenance critical during shortage-driven sourcing changes.

• Review shortage response SOPs: Distributors without formal drug shortage protocols should reference ColdChainCheck's DSCSA compliance guide for inventory management best practices. Entities scored "Good" or "Excellent" (309 total) typically maintain documented shortage escalation procedures.

• Monitor FDA updates: The FDA Drug Shortages Database updates in real-time. Bookmark the oseltamivir shortage entry and check weekly for revised resupply estimates or additional affected presentations. ColdChainCheck tracks FDA enforcement actions and shortage developments in the regulatory alerts section.

Disclaimer: This article provides informational content based on publicly available FDA data as of January 14, 2025. It is not legal or regulatory advice. Wholesale drug distributors should consult with legal counsel and refer directly to FDA guidance when making sourcing and compliance decisions.